What is the 13F Pro Quality Score for TOVX?

13F Pro ranks Theriva Biologics, Inc. (TOVX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TOVX's current score at https://13fpro.ai/research/TOVX (free sign-up required for the full ranking).

Which hedge funds own the most TOVX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TOVX include GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, UBS Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TOVX as soon as new 13F filings post.

Where does 13F Pro source TOVX data?

All Theriva Biologics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Theriva Biologics, Inc. files with the SEC under CIK 894158. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TOVX in?

Theriva Biologics, Inc. (TOVX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TOVX research updated on 13F Pro?

TOVX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Theriva Biologics, Inc.(TOVX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 894158 TOVX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TOVX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Theriva Biologics, Inc. (TOVX), a Healthcare sector company. TOVX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Theriva Biologics, Inc. reports quarterly revenue of $300.0K, net income of $-2.0M, free cash flow of $-2.5M. Top institutional holders of TOVX by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, UBS Group AG, based on the most recent SEC filings. TOVX trades on the NYSE exchange and files with the SEC under CIK 894158. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TOVX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Theriva Biologics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$300.0K

Net Income

Q1 2026

$-2.0M

Free Cash Flow

Q1 2026

$-2.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

—FY 2025

FY22 $-19.7MFY23 $-18.3MFY24 —FY25 —

Operating Income

+8.7% YoY

$-24.1MFY 2025

FY22 $-21.6MFY23 $-21.4MFY24 $-26.3MFY25 $-24.1M

EPS (Diluted)

+89.1% YoY

$-2.08FY 2025

FY22 $-0.05FY23 $-1.14FY24 $-19.03FY25 $-2.08

Total Assets

+8.2% YoY

$38.2MFY 2025

FY22 $71.9MFY23 $55.2MFY24 $35.4MFY25 $38.2M

Total Debt

+1716.3% YoY

$1.7MFY 2025

FY22 $278.0KFY23 $225.0KFY24 $92.0KFY25 $1.7M

Op. Cash Flow

+1.6% YoY

$-16.7MFY 2025

FY22 $-19.1MFY23 $-19.0MFY24 $-16.9MFY25 $-16.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Net Income	—	—	$-18.3M +6.8%	$-19.7M -96.0%	$-10.0M +34.4%	$-15.3M
Operating Income	$-24.1M +8.7%	$-26.3M -22.9%	$-21.4M +0.7%	$-21.6M -112.4%	$-10.2M +35.1%	$-15.7M
EPS (Diluted)	$-2.08 +89.1%	$-19.03 -1570.5%	$-1.14 -2074.0%	$-0.05 -1915.4%	$-0.00	—
Total Assets	$38.2M +8.2%	$35.4M -36.0%	$55.2M -23.2%	$71.9M +754.5%	$8.4M -51.2%	$17.2M
Total Debt	$1.7M +1716.3%	$92.0K -59.1%	$225.0K -19.1%	$278.0K	—	—
Operating Cash Flow	$-16.7M +1.6%	$-16.9M +10.8%	$-19.0M +0.5%	$-19.1M -56.8%	$-12.2M +12.3%	$-13.9M

AI Insight: TOVX Financial Trends

TOVX remains pre-revenue with persistent operating losses, though quarterly cash burn has narrowed to -$2M in Q1 2026 from a peak of -$5M.

• Operating loss shrank from -$8M in Q2 2024 to -$2M in Q1 2026, suggesting meaningful reduction in quarterly spend.

• Operating cash outflow moderated from -$5M in Q4 2024 to -$2M in Q1 2026, the lowest burn in the dataset.

• Revenue remains effectively zero through Q1 2026 — no commercial inflection visible across the entire eight-quarter span.

⚠ Q2 2025 operating loss spiked to -$13M before reverting — one-time or recurring cost driver warrants close scrutiny.

⚠ Total debt appeared at $2M in Q4 2025 with no prior balance — monitor for further debt accumulation given zero revenue.

AI Insight: TOVX Ratio Trends

All ratio data is absent across every period — no trends can be derived for TOVX.

• No OpMargin, NPM, ROE, ROA, ROIC, or D/E data is available for any quarter from Q2 2024 through Q1 2026.

⚠ Complete data absence prevents any financial assessment; await populated filings before drawing conclusions.

Get alerted when TOVX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Theriva Biologics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TOVX

GEODE CAPITAL MANAGEMENT, LLC
$88.2K450,263 sh
VANGUARD FIDUCIARY TRUST CO
$47.4K241,780 sh
UBS Group AG
$44.2K225,624 sh
VANGUARD CAPITAL MANAGEMENT LLC
$37.7K192,404 sh
JANE STREET GROUP, LLC
$34.7K177,034 sh
Ikarian Capital, LLC
$21.9K112,076 sh
TWO SIGMA SECURITIES, LLC
$20.6K105,241 sh
XTX Topco Ltd
$18.5K94,620 sh
BOOTHBAY FUND MANAGEMENT, LLC
$5.4K27,646 sh
MORGAN STANLEY
$4.6K23,602 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$88.2K	450,263
VANGUARD FIDUCIARY TRUST CO	$47.4K	241,780
UBS Group AG	$44.2K	225,624
VANGUARD CAPITAL MANAGEMENT LLC	$37.7K	192,404
JANE STREET GROUP, LLC	$34.7K	177,034
Ikarian Capital, LLC	$21.9K	112,076
TWO SIGMA SECURITIES, LLC	$20.6K	105,241
XTX Topco Ltd	$18.5K	94,620
BOOTHBAY FUND MANAGEMENT, LLC	$5.4K	27,646
MORGAN STANLEY	$4.6K	23,602

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TOVX on your watchlist

Track score changes the day Theriva Biologics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TOVX a good stock to buy?

13F Pro's AI-powered analysis of Theriva Biologics, Inc. (TOVX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TOVX are available on the TOVX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TOVX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TOVX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Theriva Biologics, Inc.'s investment landscape.